CAV Regimen Bridging to HSCT for R/R AL

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 17, 2024

Study Completion Date

November 17, 2024

Conditions
Acute Leukemia, RelapsedAcute Leukemia Refractory
Interventions
PROCEDURE

CAV regimen bridging to HSCT

The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The Second People's Hospital of Huai'an

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT05190549 - CAV Regimen Bridging to HSCT for R/R AL | Biotech Hunter | Biotech Hunter